Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cervical insufficiency (CI), responsible for 8% of preterm births (PB), is used to describe painless cervical dilation leading to recurrent second-trimester pregnancy losses/births of otherwise normal pregnancies. Structural weakness of cervical tissue was thought to cause or contribute to these adverse outcomes. The term has also been applied to women with one or two such losses/births or at risk for second-trimester pregnancy loss/birth. Cervical pessary and cervical cerclage are both considered as preventive treatments in women at risk for PB. This study aims to demonstrate that the cervical pessary could reduce the preterm birth rate before 37 weeks of gestation in women with prior PB due to cervical insufficiency or in women with prior PB and a short cervix in the current pregnancy.
Methods/Design: This is an open-label, pilot, multicentre, prospective, randomised controlled trial (RCT). Enrolees are women with singleton pregnancies and previous PB based on CI (primary intervention, <16 weeks) or in case of previous PB and a short cervical length in current pregnancy ≤ 25 mm (secondary intervention, <24 weeks). Women are randomised (1:1) either to cervical cerclage or pessary treatment. The primary outcome is the spontaneous preterm birth rate before 34 weeks of gestation. The sample size was calculated, as a pilot study, based on the estimated population that we will be able to recruit during the duration of the trial: 60 women, 30 for each group (cervical cerclage and cervical pessary group) to observe, at least a reduction in the PB rate < 34 weeks from 34% to 27% in the pessary group, as does cerclage.
Discussion: The outcome of this study will show the effectiveness of a cervical cerclage and of a cervical pessary in this group of patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cerclage | Experimental | Cervical cerclage. |
|
| Cervical pessary | Experimental | Cervical pessary |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cerclage | Procedure | Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Spontaneous delivery before 34 complete weeks | Spontaneous delivery before 34 complete weeks | Before 34 weeks of gestation |
| Measure | Description | Time Frame |
|---|---|---|
| Spontaneous delivery before 28 complete weeks | Spontaneous delivery before 28 complete weeks | Before 28 weeks of gestation |
| Spontaneous delivery before 37 complete weeks | Spontaneous delivery before 37 complete weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Maria Goya, PhD | Hospital Vall d'Hebrón | Principal Investigator |
| Andrea Gascón, MD | Hospital Vall d'Hebrón | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Vall d'Hebron | Barcelona | 08035 | Spain |
Not provided
| ID | Term |
|---|---|
| D002581 | Uterine Cervical Incompetence |
| ID | Term |
|---|---|
| D002577 | Uterine Cervical Diseases |
| D014591 | Uterine Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D023802 | Cerclage, Cervical |
| ID | Term |
|---|---|
| D013513 | Obstetric Surgical Procedures |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
Cervical pessary vs. Cervical cerclage
Not provided
Not provided
Not provided
Not provided
| Cervical pessary | Device | The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain. |
|
| Before 37 weeks of gestation |
| Foetal and neonatal death | Foetal and neonatal death | During pregnancy and during the first 28 days of newborn or NICU stay |
| Neonatal morbidity | Neonatal morbidity | 28 days of newborn or during NICU stay |
| Maternal side effects | Maternal side effects | During pregnancy |
| Maternal morbidity | Maternal morbidity | during pregnancy |
| Number of participants with chorioamnionitis infection | Number of participants with chorioamnionitis infection | During pregnancy |
| Hospitalisation for threatened preterm labour | Hospitalisation for threatened preterm labour | During pregnancy |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000026 | Abortion, Habitual |
| D000022 | Abortion, Spontaneous |
| D011248 | Pregnancy Complications |
| D000091662 | Genital Diseases |